AKI-Sapere Predicts Risk of Cardiac Procedure-Associated Adverse Events
AKI-Sapere is the first in a series of blood tests being developed to stratify patients by risk of devastating adverse events. The test is administered prior to cardiovascular interventions and results allow personalized treatment plans, improving outcomes and saving lives.
As a risk prediction score, AKI-Sapere is comprised of aging biomarkers and clinical variables and identifies patients at high risk of acute kidney injury (AKI) after cardiac revascularization procedures (surgery or catheterization/percutaneous coronary intervention).
A multi-center clinical validation trial is ongoing.
Unpublished data, Sapere Bio
To learn more:
Nadim et al 2018 ”Cardiac and Vascular Surgery-Associated AKI: The 20th International Consensus Conference of the ADQI” JAHA 7(11)
Bihorac and Hobson 2017 “Precision perioperative care protects the kidneys” Nature Reviews | Nephrology 14(1):8-10
"Your aim is laudable and feasible"
Key Opinion Leader, Cardiothoracic Surgery